Extended Data Fig. 5: Neutralization potency of mRNA vaccine sera and convalescent sera (before SARS-CoV-2 B.1.1.7) against pseudotyped virus bearing spike mutations in the B.1.1.7 lineage with and without the E484K substitution in the RBD.
From: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
All virus variants were in a spike(D614G) background. Neutralization potency of the sera from the first (left; n = 37) and the second (middle, n = 21) vaccine dose and of convalescent plasma (CP) (right; n = 27) against wild-type SARS-CoV-2, the B.1.1.7 variant with spike(N501Y, A570D, ΔH69/ΔV70, Δ144, P681H, T716I, S982A, D1118H) and the B.1.1.7 variant with spike(N501Y, A570D, ΔH69/ΔV70, Δ144, P681H, T716I, S982A, D1118H) and the additional E484K substitution. Data are GMT ± s.d. representative of two independent experiments each with two technical repeats. Wilcoxon matched-pairs signed-rank test; **P < 0.01, ***P < 0.001, **** P < 0.0001.
